Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Assess and address
How can patient perceptions of asthma control affect disease management?
24-hour action
Relvar contains a unique combination of long-lasting molecules – fluticasone furoate and vilanterol.1 This means that once-daily dosing with Relvar provides continuous 24-hour efficacy with no drop in effectiveness towards the end of the 24-hour dosing interval.1–3
This graph has been reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com. The original graph was published in David I Bernstein, Eric D Bateman, Ashley Woodcock, William T Toler, Richard Forth, Loretta Jacques, Carol Nunn, Paul M O'Byrne. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. Journal of Asthma 2015;52:1073–1083.
Fluticasone furoate and vilanterol are not licensed as monotherapies for patients with asthma in all markets. Relvar is not indicated for the relief of acute bronchospasm.
While therapeutic effect is even seen post-24 hours, the approved and recommended dosing for Relvar is once-daily.1
Reprinted from Respiratory Medicine, Vol 119, Braithwaite I, et al, Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma, pp115–121, Copyright © 2016, with permission from Elsevier. The same results were first published in Braithwaite I, et al. Respir Med 2016;119:115–121.
Fluticasone furoate and vilanterol are not licensed as monotherapies for patients with asthma in all markets. Relvar is not indicated for the relief of acute bronchospasm.
Discover Relvar
Abbreviations
AE, adverse event; CI, confidence interval; FEV1, forced expiratory volume in one second; LS, least square.
Relvar Safety Information4
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Undesirable effects
Very Common: Headache, Nasopharyngitis.
Common: Infections and infestations, Oropharyngeal pain, Sinusitis, Pharyngitis, Rhinitis, Cough, Dysphonia, Abdominal pain, Arthralgia, Back pain, Fractures, Muscle spasms and Pyrexia.
References
- Global Datasheet Fluticasone furoate/vilanterol: v13, September 2022.
- Bernstein DI, et al. J Asthma 2015;52:1073–1083.
- Braithwaite I, et al. Respir Med 2016;119:115–121.
- Relvar Prescribing Information.
GSK does not recommend, endorse, or accept liability for the 3rd party sites.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني https://moh.gov.om/en/ : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies
PM-RCH-FFV-WCNT-250001 Date of preparation: July 2025
